PAZOPANIB, a new and selective angiogenesis (formation of blood vessels) inhibitor involved in tumour growth and survival, has recently been launched in Malaysia. It is a once-daily, oral medication indicated for the treatment of advanced and/or metastatic renal cell carcinoma (RCC), the most common type of kidney cancer among adults.
Every year, the global incidence of RCC rises by 2%. In Malaysia, there were an estimated 383 cases of kidney and urinary organs cancer in 2006.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
